title: A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant.
abstract: OBJECTIVE
  Preservation of renal function is an important issue after living donor liver transplant. We aimed to examine the renal protective efficacy of telbivudine in hepatitis B virus-infected patients after living donor liver transplant.
  
  
  METHODS
  In this retrospective study, we compared 18 patients who received telbivudine 600 mg once per day and 23 patients who received entecavir 1 mg once per day after living donor liver transplant. Clinical data were obtained through chart review and included Model for End-Stage Liver Disease score and pre- and postoperative aspartate aminotransferase, alanine aminotransferase, and creatinine levels and estimated glomerular filtration rate.
  
  
  RESULTS
  Posttransplant estimated glomerular filtration rates and creatinine levels were calculated, and improvement of renal function was found in the group of patients who received telbivudine. Significant improvements were shown in estimated glomerular filtration rates started after 9 months of administration and creatinine levels after 12 months compared with patients who received entecavir.
  
  
  CONCLUSIONS
  In our study, long-term telbivudine therapy is associated with a sustained improvement of renal function in patients with hepatitis B virus infection after living donor liver transplant.
authors.affiliation: From the Department of General Surgery, Changhua Christian Hospital, Changhua, Taiwan.
authors.forename: Kuo-Hua
authors.initials: KH
authors.lastname: Lin
authors.forename: Yao-Li
authors.initials: YL
authors.lastname: Chen
authors.forename: Ping-Yi
authors.initials: PY
authors.lastname: Lin
authors.forename: Chia-En
authors.initials: CE
authors.lastname: Hsieh
authors.forename: Chih-Jan
authors.initials: CJ
authors.lastname: Ko
authors.forename: Chia-Cheng
authors.initials: CC
authors.lastname: Lin
authors.forename: Ying-Zi
authors.initials: YZ
authors.lastname: Ming
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003404:Creatinine / Q000097:blood; D003430:Cross-Sectional Studies; D058625:End Stage Liver Disease / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery* / Q000821:virology; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D016031:Liver Transplantation / Q000379:methods*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D020127:Recovery of Function; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077712:Telbivudine; C413685:entecavir; D006147:Guanine; D003404:Creatinine; D013936:Thymidine